ArticleMolecular therapy : the journal of the American Society of Gene Therapy2015
Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 96 citations in OpenAlex.
- Targeting CTC Heterogeneity: Aptamer-Based Liquid Biopsy Predicts Outcome in Lung Cancer.Cancers · 2025Article
- Apoptotic extracellular vesicles: emerging biomarkers for cancer and neurodegenerative disease diagnostics.Frontiers in immunology · 2025Review
- Comprehensive Analysis of the Potential Toxicity of Magnetic Iron Oxide Nanoparticles for Medical Applications: Cellular Mechanisms and Systemic Effects.International journal of molecular sciences · 2024Review
- Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance.Cancer metastasis reviews · 2024Review
- Review
- Circulating Tumor Cells Adhesion: Application in Biosensors.Biosensors · 2023Review
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- Development of DNA aptamers for visualization of glial brain tumors and detection of circulating tumor cells.Molecular therapy. Nucleic acids · 2023Article
- Article
- Monitoring of breast cancer progression via aptamer-based detection of circulating tumor cells in clinical blood samples.Frontiers in molecular biosciences · 2023Article
- Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity.Pharmaceutics · 2022Article
- Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.Molecules (Basel, Switzerland) · 2022Article
- Emerging Advances of Detection Strategies for Tumor-Derived Exosomes.International journal of molecular sciences · 2022Review
- The Influence of Clusterin Glycosylation Variability on Selected Pathophysiological Processes in the Human Body.Oxidative medicine and cellular longevity · 2022Review
- Development of Electrochemical Aptasensor for Lung Cancer Diagnostics in Human Blood.Sensors (Basel, Switzerland) · 2021Article
- Uptake mechanisms of cell-internalizing nucleic acid aptamers for applications as pharmacological agents.RSC medicinal chemistry · 2021Review
- The role of SAXS and molecular simulations in 3D structure elucidation of a DNA aptamer against lung cancer.Molecular therapy. Nucleic acids · 2021Article
- Advances in Oligonucleotide Aptamers for NSCLC Targeting.International journal of molecular sciences · 2020Review
- The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.Scientific reports · 2020Article
- Aptamer-based approaches forResearch in pharmaceutical sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor cells (CTCs) are rare cells and valuable clinical markers of prognosis of metastasis formation and prediction of patient survival. Most CTC analyses are based on the antibody-based detection of a few epithelial markers; therefore miss an important portion of mesenchymal cancer cells circulating in blood. In this work, we selected and identified DNA aptamers as specific affinity probes that bind to lung adenocarcinoma cells derived from postoperative tissues. The unique feature of our selection strategy is that aptamers are produced for lung cancer cell biomarkers in their native state and conformation without previous knowledge of the biomarkers. The aptamers did not bind to normal lung cells and lymphocytes, and had very low affinity to A549 lung adenocarcinoma culture. We applied these aptamers to detect CTCs, apoptotic bodies, and microemboli in clinical samples of peripheral blood of lung cancer and metastatic lung cancer patients. We identified aptamer-associated protein biomarkers for lung cancer such as vimentin, annexin A2, annexin A5, histone 2B, neutrophil defensin, and clusterin. Tumor-specific aptamers can be produced for individual patients and synthesized many times during anticancer therapy, thereby opening up the possibility of personalized diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.